Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|August 23, 2016
Adare Pharmaceuticals Company Profile
Advertisement
Adare is a global specialty pharmaceutical company focused on developing innovative products that can improve the lives of patients whose treatment needs are not fully addressed by current medications. Adare transforms medicines tailored to the needs of the evolving global healthcare market-creating value for patients and partners.
With extensive experience across a broad range of therapeutic areas, Adare is actively pursuing growth in its proprietary pipeline, including development, acquisitions, and expanding its GI portfolio with its natural bacterial product franchise.
Innovative solutions for patients around the world
By applying its capabilities and expertise, Adare delivers innovative solutions that help solve a broad range of challenges.
With a wide range of proprietary technologies (taste-masking & ODTs, customized drug release and bioavailability enhancement), Adare can help you overcome complex formulation challenges and add valuable IP to commercialized products and products in development.
Over 40 products incorporating the proprietary technologies of Adare have been commercialized around the world. Adare also has an extensive patent portfolio, which includes more than 360 granted patents and 225 pending patent applications.
Experience a partnership focused on the needs of patients and your company's goals, contact us at
Contact Details :
Adare Pharmaceuticals
Website:
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement